These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 32347755

  • 1. Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data.
    Costa OS, Beyer-Westendorf J, Ashton V, Milentijevic D, Moore KT, Bunz TJ, Coleman CI.
    Curr Med Res Opin; 2020 Jul; 36(7):1081-1088. PubMed ID: 32347755
    [Abstract] [Full Text] [Related]

  • 2. Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data.
    Costa OS, Beyer-Westendorf J, Ashton V, Milentijevic D, Moore KT, Bunz TJ, Coleman CI.
    J Thromb Thrombolysis; 2021 Feb; 51(2):349-358. PubMed ID: 32588288
    [Abstract] [Full Text] [Related]

  • 3. Rivaroxaban Versus Warfarin in African American Patients with Nonvalvular Atrial Fibrillation.
    Coleman CI, Thompson S, Ashton V, Palladino M, Bunz TJ.
    J Natl Med Assoc; 2020 Aug; 112(4):395-401. PubMed ID: 32493618
    [Abstract] [Full Text] [Related]

  • 4. Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin.
    Coleman CI, Costa OS, Brescia CW, Vardar B, Abdelgawwad K, Sood N.
    Cardiovasc Diabetol; 2021 Feb 26; 20(1):52. PubMed ID: 33637082
    [Abstract] [Full Text] [Related]

  • 5. Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation.
    Martinez BK, Baker WL, Sood NA, Bunz TJ, Meinecke AK, Eriksson D, Coleman CI.
    Pharmacotherapy; 2019 Feb 26; 39(2):196-203. PubMed ID: 30597611
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.
    Martinez BK, Sood NA, Bunz TJ, Coleman CI.
    J Am Heart Assoc; 2018 Apr 13; 7(8):. PubMed ID: 29654196
    [Abstract] [Full Text] [Related]

  • 7. Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Severe Kidney Disease or Undergoing Hemodialysis.
    Coleman CI, Kreutz R, Sood NA, Bunz TJ, Eriksson D, Meinecke AK, Baker WL.
    Am J Med; 2019 Sep 13; 132(9):1078-1083. PubMed ID: 31054829
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M, Choi Y, Eisenberg R, Rao D, Tolu S, Gao J, Mowrey W, Billett HH.
    Lancet Haematol; 2019 Jul 13; 6(7):e359-e365. PubMed ID: 31133411
    [Abstract] [Full Text] [Related]

  • 9. Rivaroxaban Versus Warfarin for Management of Obese African Americans With Non-Valvular Atrial Fibrillation or Venous Thromboembolism: A Retrospective Cohort Analysis.
    Costa OS, Beyer-Westendorf J, Ashton V, Milentijevic D, Moore KT, Bunz TJ, Coleman CI.
    Clin Appl Thromb Hemost; 2020 Jul 13; 26():1076029620954910. PubMed ID: 33085526
    [Abstract] [Full Text] [Related]

  • 10. Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1.
    Coleman CI, Turpie AGG, Bunz TJ, Eriksson D, Sood NA, Baker WL.
    Eur Heart J Cardiovasc Pharmacother; 2019 Apr 01; 5(2):64-69. PubMed ID: 30020424
    [Abstract] [Full Text] [Related]

  • 11. Risk of Stroke Outcomes in Atrial Fibrillation Patients Treated with Rivaroxaban and Warfarin.
    Milentijevic D, Lin JH, Connolly N, Chen YW, Kogan E, Shrivastava S, Sjoeland E, Alberts MJ.
    J Stroke Cerebrovasc Dis; 2021 May 01; 30(5):105715. PubMed ID: 33743312
    [Abstract] [Full Text] [Related]

  • 12. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G, Blotière PO, Bouillon K, Billionnet C, Ricordeau P, Alla F, Zureik M.
    Circulation; 2015 Sep 29; 132(13):1252-60. PubMed ID: 26199338
    [Abstract] [Full Text] [Related]

  • 13. Comparative Effectiveness and Safety of Rivaroxaban and Warfarin Among Nonvalvular Atrial Fibrillation (NVAF) Patients with Obesity and Polypharmacy in the United States (US).
    Berger JS, Laliberté F, Kharat A, Lejeune D, Moore KT, Jung Y, Lefebvre P, Ashton V.
    Adv Ther; 2021 Jul 29; 38(7):3771-3788. PubMed ID: 34031859
    [Abstract] [Full Text] [Related]

  • 14. Kidney, limb and ophthalmic complications, and death in patients with nonvalvular atrial fibrillation and type 2 diabetes prescribed rivaroxaban or warfarin: an electronic health record analysis.
    Costa OS, O'Donnell B, Vardar B, Abdelgawwad K, Brescia CW, Sood N, Coleman CI.
    Curr Med Res Opin; 2021 Sep 29; 37(9):1493-1500. PubMed ID: 34166150
    [Abstract] [Full Text] [Related]

  • 15. A RIVA-DM Subanalysis Investigating Patients With Nonvalvular Atrial Fibrillation and Type 2 Diabetes Aged Under Versus Over 80 Years.
    Coleman CI, Costa OS, Brescia CW, Vardar B, Abdelgawwad K, Hofmeister L, Sood N.
    Clin Appl Thromb Hemost; 2022 Sep 29; 28():10760296221133083. PubMed ID: 36377242
    [Abstract] [Full Text] [Related]

  • 16. Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation: The NAXOS Study.
    Van Ganse E, Danchin N, Mahé I, Hanon O, Jacoud F, Nolin M, Dalon F, Lefevre C, Cotté FE, Gollety S, Falissard B, Belhassen M, Steg PG.
    Stroke; 2020 Jul 29; 51(7):2066-2075. PubMed ID: 32539675
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and heart failure.
    Martinez BK, Bunz TJ, Eriksson D, Meinecke AK, Sood NA, Coleman CI.
    ESC Heart Fail; 2019 Feb 29; 6(1):10-15. PubMed ID: 30299591
    [Abstract] [Full Text] [Related]

  • 18. Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients.
    Deitelzweig S, Luo X, Gupta K, Trocio J, Mardekian J, Curtice T, Lingohr-Smith M, Menges B, Lin J.
    Curr Med Res Opin; 2017 Oct 29; 33(10):1745-1754. PubMed ID: 28849676
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery disease.
    Coleman CI, Baker WL, Meinecke AK, Eriksson D, Martinez BK, Bunz TJ, Alberts MJ.
    Eur Heart J Cardiovasc Pharmacother; 2020 Jul 01; 6(3):159-166. PubMed ID: 31549153
    [Abstract] [Full Text] [Related]

  • 20. Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study.
    Coleman CI, Antz M, Bowrin K, Evers T, Simard EP, Bonnemeier H, Cappato R.
    Curr Med Res Opin; 2016 Dec 01; 32(12):2047-2053. PubMed ID: 27633045
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.